2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
CardiologiaSobre o estudo
- Desenho
- Diretriz clínica
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Circulation
- Publicado em
- 8 mai 2024
- Citações
- 759
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
Steve R Ommen, Carolyn Y Ho, Irfan M Asif, Seshadri Balaji, Michael A Burke, Sharlene M Day, Joseph A Dearani, Kelly C Epps, Lauren Evanovich, Victor A Ferrari et al.
Descritores MeSH
- American Heart Association
- Cardiology
- Cardiomyopathy, Hypertrophic
- Humans
- United States
- Disease Management
Veja também
Estudos relacionados
- 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
- 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
- 2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
- 2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
- Impacto a longo prazo do aficamten nas medidas de desfecho relatadas pelo paciente na cardiomiopatia hipertrófica obstrutiva: resultados do FOREST-HCM
- Eficácia e Segurança das Terapias Farmacológicas na Cardiomiopatia Hipertrófica Não Obstrutiva: Revisão Sistemática